Abstract library

6 results for "Circelli".
#860 Expression and Prognostic Role of CXCR4/CXCL12/CXCR7 and mTOR Pathways in Neuroendocrine Tumors (NETs)
Introduction: The chemokine receptor CXCR4 interacts with the ligand CXCL12 to exert proliferative and chemotactic effects. CXCR4 activates mTOR through phosphorylation of its two effectors downstream:4EBP1and S6K
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Doctor Luisa Circelli
#901 Impact of Long-Acting Octreotide in Patients with Early-Stage MEN1-Related Duodeno-Pancreatic Neuroendocrine Tumors
Introduction: Somatostatin analogues (SSA) represent one of the main therapeutic options in patients affected by functioning well-differentiated neuroendocrine tumors (NETs). There are no studies specifically focusing on NETs associated with Multiple Endocrine Neoplasia type 1 (MEN1).
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Valeria Ramundo
#1109 Expression and Role of the CXCR4/CXCL12/CXCR7 Axis and Crosstalk with the mTOR Pathway in Neuroendocrine Tumors (NETs)
Introduction: Chemokine receptor CXCR4 has been shown to signal on mTOR pathway in gastric and renal cancer. CXCR4 interacts with the chemokine CXCL12 to exert proliferative and chemotactic effects.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: student Concetta Sciammarella
#1756 Somatostatin Analogs in Patients with Multiple Endocrine Neoplasia Type 1 and Zollinger-Ellison Syndrome: Efficacy and Safety
Introduction: Zollinger-Ellison syndrome (ZES) can cause severe complications. In multiple endocrine neoplasia type 1 (MEN1) related ZES, surgery has a controversial role and proton pump inhibitors (PPI) are usually first-line therapy, although some concerns regarding long-term use. Somatostatin analogs (SSA) both reduce hypergastrinemia and have an antiproliferative role.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Roberta Modica
#1758 Efficacy and Safety of Low Dose Vandetanib in Metastatic Medullary Thyroid Cancer
Introduction: Medullary thyroid cancer (MTC) is an aggressive thyroid malignancy. Vandetanib is a tyrosine kinase inhibitor approved for locally advanced or metastatic MTC, administered orally 300 mg/daily. Diarrhea, hypertension and QT prolongation are common side effects and may require withdrawal or dose reduction.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: MD Roberta Modica
#1770 Cytokines as Predictive Factors of Response to Somatostatin Analogues in Patients with Neuroendocrine Tumour
Introduction: The somatostatin analogues are a major therapeutic advance in neuroendocrine tumor (NET) treatment and have multiple modulatory effects on the immune system.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Concetta Sciammarella